Gen-Probe Logs Record Clinical Dx Sales, Weaker Blood Screening Revenues in Q4 2010
February 17, 2011
Gen-Probe Logs Record Clinical Dx Sales, Weaker Blood Screening Revenues in Q4 2010
The company also updated investors on the uptake of its recently launched Panther molecular diagnostics platform in Europe, and on plans for US commercialization and test menu build-out for the instrument.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Hologic's Gen-Probe Wins Judgment in IP Suit Against BD, but Dispute Remain Unresolved
October 4, 2012 / PCR Insider - Gen-Probe to Serve as 'Cornerstone' of Hologic's MDx Franchise, Primarily Through STD Test Offerings
May 3, 2012 / PCR Insider - Jeffries Survey on Gen-Probe Offerings Forecasts 300 Panther Placements by End of 2013
April 19, 2012 / PCR Insider - Q&A: New Novartis Dx President Discusses Nucleic Acid Testing, Blood Screening Business
March 15, 2012 / PCR Insider - Gen-Probe to Add Real-Time PCR Capability to Next-Gen Panther MDx Platform
January 19, 2012 / PCR Insider